760 related articles for article (PubMed ID: 34390083)
21. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori.
Wu TS; Hsu PI; Kuo CH; Hu HM; Wu IC; Wang SSW; Chen YH; Wu DC; Su WW; Kuo FC
J Dig Dis; 2017 Sep; 18(9):537-542. PubMed ID: 28644575
[TBL] [Abstract][Full Text] [Related]
22. Helicobacter pylori Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on H. pylori Management.
Tepes B; Brglez Jurecic N; Tepes K; Espada Sanchez M; Perez Nyssen O; O'Morain C; Mégraud F; Gisbert J
Dig Dis; 2021; 39(4):318-324. PubMed ID: 33099549
[TBL] [Abstract][Full Text] [Related]
23. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
Hu TH; Chuah SK; Hsu PI; Wu DC; Tai WC; Chiu YC; Wu KL; Kuo CM; Hu ML
Am J Med Sci; 2011 Sep; 342(3):177-81. PubMed ID: 21804375
[TBL] [Abstract][Full Text] [Related]
24. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
[TBL] [Abstract][Full Text] [Related]
25. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg).
Nyssen OP; Vaira D; Pérez Aísa Á; Rodrigo L; Castro-Fernandez M; Jonaitis L; Tepes B; Vologzhanina L; Caldas M; Lanas A; Lucendo AJ; Bujanda L; Ortuño J; Barrio J; Huguet JM; Voynovan I; Lasala JP; Sarsenbaeva AS; Fernandez-Salazar L; Molina-Infante J; Jurecic NB; Areia M; Gasbarrini A; Kupčinskas J; Bordin D; Marcos-Pinto R; Lerang F; Leja M; Buzas GM; Niv Y; Rokkas T; Phull P; Smith S; Shvets O; Venerito M; Milivojevic V; Simsek I; Lamy V; Bytzer P; Boyanova L; Kunovský L; Beglinger C; Doulberis M; Marlicz W; Goldis A; Tonkić A; Capelle L; Puig I; Megraud F; Morain CO; Gisbert JP;
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2243-2257. PubMed ID: 34954341
[TBL] [Abstract][Full Text] [Related]
26. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
Cao Z; Chen Q; Zhang W; Liang X; Liao J; Liu W; Xiao S; Lu H
Scand J Gastroenterol; 2015; 50(10):1185-90. PubMed ID: 25881966
[TBL] [Abstract][Full Text] [Related]
27. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
28. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
[TBL] [Abstract][Full Text] [Related]
29. The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance.
Huang TH; Yang SC; Tai WC; Liang CM; Kuo CM; Yao CC; Wu CK; Kuo YH; Chou YP; Lee CH; Wu KL; Chuah SK
Biomed J; 2021 Dec; 44(6 Suppl 2):S275-S281. PubMed ID: 35292265
[TBL] [Abstract][Full Text] [Related]
30. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection.
Yee YK; Cheung TK; Chu KM; Chan CK; Fung J; Chan P; But D; Hung I; Chan AO; Yuen MF; Hsu A; Wong BC
Aliment Pharmacol Ther; 2007 Oct; 26(7):1063-7. PubMed ID: 17877513
[TBL] [Abstract][Full Text] [Related]
31. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea.
Choe JW; Jung SW; Kim SY; Hyun JJ; Jung YK; Koo JS; Yim HJ; Lee SW
Helicobacter; 2018 Apr; 23(2):e12466. PubMed ID: 29369454
[TBL] [Abstract][Full Text] [Related]
32. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of second-line regimens for
Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
[TBL] [Abstract][Full Text] [Related]
34. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea.
Lee H; Hong SN; Min BH; Lee JH; Rhee PL; Lee YC; Kim JJ
Dig Liver Dis; 2015 Feb; 47(2):114-8. PubMed ID: 25467826
[TBL] [Abstract][Full Text] [Related]
35. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.
Wang Z; Wu S
Singapore Med J; 2012 Apr; 53(4):273-6. PubMed ID: 22511052
[TBL] [Abstract][Full Text] [Related]
36. [Levofloxacin-azithromycin combined triple therapy for Helicobacter pylori eradication].
Kang MS; Park DI; Yun JW; Oh SY; Yoo TW; Park JH; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI
Korean J Gastroenterol; 2006 Jan; 47(1):30-6. PubMed ID: 16434866
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.
Cheon JH; Kim N; Lee DH; Kim JM; Kim JS; Jung HC; Song IS
Helicobacter; 2006 Feb; 11(1):46-51. PubMed ID: 16423089
[TBL] [Abstract][Full Text] [Related]
38. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
Hsu PI; Wu DC; Chen A; Peng NJ; Tseng HH; Tsay FW; Lo GH; Lu CY; Yu FJ; Lai KH
Eur J Clin Invest; 2008 Jun; 38(6):404-9. PubMed ID: 18435764
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
Kuo CH; Hu HM; Kuo FC; Hsu PI; Chen A; Yu FJ; Tsai PY; Wu IC; Wang SW; Li CJ; Weng BC; Chang LL; Jan CM; Wang WM; Wu DC
J Antimicrob Chemother; 2009 May; 63(5):1017-24. PubMed ID: 19246508
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial.
Alhalabi M; Alassi MW; Alaa Eddin K; Cheha K
BMC Infect Dis; 2021 Jul; 21(1):642. PubMed ID: 34218802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]